# Isabelle Cremer

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 89 papers | 6,660 citations | 45 h-index | 81 g-index |
| 101 ext. papers | 8,064 ext. citations | 7.1 avg, IF | 5.24 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 89 | Immunodynamics of explanted human tumors for immuno-oncology. *EMBO Molecular Medicine*, **2021**, 13, e12850 | 12 | 2 |
| 88 | Autophagy Modulation by Viral Infections Influences Tumor Development. *Frontiers in Oncology*, **2021**, 11, 743780 | 5.3 | 2 |
| 87 | Metabolic features of cancer cells impact immunosurveillance **2021**, 9, | | 2 |
| 86 | To Vaccinate or not: Influenza Virus and Lung Cancer Progression. *Trends in Cancer*, **2021**, 7, 573-576 | 12.5 | 2 |
| 85 | Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma. *European Journal of Cancer*, **2020**, 135, 221-229 | 7.5 | 5 |
| 84 | Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. *Methods in Enzymology*, **2020**, 632, 15-25 | 1.7 | 1 |
| 83 | Toll-Like Receptors (TLRs) in the Tumor Microenvironment (TME): A Dragon-Like Weapon in a Non-fantasy Game of Thrones. *Advances in Experimental Medicine and Biology*, **2020**, 1263, 145-173 | 3.6 | 8 |
| 82 | Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions **2020**, 8, | | 24 |
| 81 | NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. *Seminars in Immunology*, **2020**, 48, 101407 | 10.7 | 12 |
| 80 | Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood. *Methods in Enzymology*, **2020**, 631, 277-287 | 1.7 | |
| 79 | NK Cells in the Human Lungs. *Frontiers in Immunology*, **2019**, 10, 1263 | 8.4 | 23 |
| 78 | Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. *Journal of Thoracic Oncology*, **2019**, 14, 844-856 | 8.9 | 27 |
| 77 | Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients **2019**, 7, 312 | | 36 |
| 76 | Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. *OncoImmunology*, **2019**, 8, e1505174 | 7.2 | 20 |
| 75 | Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 928-940 | 10.2 | 38 |
| 74 | Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. *OncoImmunology*, **2018**, 7, e1423184 | 7.2 | 26 |
| 73 | TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. *OncoImmunology*, **2018**, 7, e1386826 | 7.2 | 16 |

| | | | |
|---|---|---|---|
| 72 | Immunopathogenesis of the Anti-Synthetase Syndrome. *Critical Reviews in Immunology*, **2018**, 38, 263-278 | 1.88 | 1 |
| 71 | , and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. *Clinical Cancer Research*, **2018**, 24, 5710-5723 | 12.9 | 150 |
| 70 | Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. *Immunobiology*, **2017**, 222, 89-100 | 3.4 | 111 |
| 69 | Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. *OncoImmunology*, **2017**, 6, e1163456 | 7.2 | 22 |
| 68 | Polyfunctionality of bona fide resident lung CD69 natural killer cells. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 317-318 | 11.5 | 4 |
| 67 | Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. *OncoImmunology* , **2016**, 5, e1088631 | 7.2 | 81 |
| 66 | Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. *Journal of Immunology*, **2016**, 197, 1621-30 | 5.3 | 21 |
| 65 | Trial Watch: Immunotherapy plus radiation therapy for oncological indications. *OncoImmunology*, **2016**, 5, e1214790 | 7.2 | 51 |
| 64 | Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. *OncoImmunology*, **2016**, 5, e1177692 | 7.2 | 37 |
| 63 | Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 1403-1412 | 10.2 | 34 |
| 62 | Trial Watch-Immunostimulation with cytokines in cancer therapy. *OncoImmunology*, **2016**, 5, e1115942 | 7.2 | 35 |
| 61 | Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. *Cancer Research*, **2016**, 76, 1746-56 | 10.1 | 122 |
| 60 | Trial Watch-Oncolytic viruses and cancer therapy. *OncoImmunology*, **2016**, 5, e1117740 | 7.2 | 76 |
| 59 | Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. *OncoImmunology*, **2016**, 5, e1149674 | 7.2 | 41 |
| 58 | Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. *Blood*, **2016**, 128, 3113-3124 | 2.2 | 81 |
| 57 | Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. *OncoImmunology*, **2016**, 5, e1255394 | 7.2 | 34 |
| 56 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. *OncoImmunology*, **2015**, 4, e1008814 | 7.2 | 68 |
| 55 | Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. *OncoImmunology*, **2015** , 4, e1008866 | 7.2 | 162 |

| | | | |
|---|---|---|---|
| 54 | Profiling of the three circulating monocyte subpopulations in human obesity. *Journal of Immunology*, **2015**, 194, 3917-23 | 5.3 | 64 |
| 53 | IFN-γ receptor signaling promotes regulatory T cell development and function under stress conditions. *Journal of Immunology*, **2015**, 194, 4265-76 | 5.3 | 48 |
| 52 | Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. *Annals of Oncology*, **2015**, 26, 2470-7 | 10.3 | 15 |
| 51 | Trial Watch: Adoptive cell transfer for oncological indications. *OncoImmunology*, **2015**, 4, e1046673 | 7.2 | 22 |
| 50 | Trial watch: Naked and vectored DNA-based anticancer vaccines. *OncoImmunology*, **2015**, 4, e1026531 | 7.2 | 22 |
| 49 | Dual roles of TLR7 in the lung cancer microenvironment. *OncoImmunology*, **2015**, 4, e991615 | 7.2 | 15 |
| 48 | Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. *Frontiers in Immunology*, **2015**, 6, 402 | 8.4 | 84 |
| 47 | Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. *PLoS ONE*, **2015**, 10, e0133363 | 3.7 | 11 |
| 46 | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. *OncoImmunology*, **2015**, 4, e985940 | 7.2 | 38 |
| 45 | Trial Watch: Peptide-based anticancer vaccines. *OncoImmunology*, **2015**, 4, e974411 | 7.2 | 81 |
| 44 | T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. *Diabetes*, **2014**, 63, 1966-77 | 0.9 | 152 |
| 43 | TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. *Cancer Research*, **2014**, 74, 5008-18 | 10.1 | 64 |
| 42 | Trial Watch: Chemotherapy with immunogenic cell death inducers. *OncoImmunology*, **2014**, 3, e27878 | 7.2 | 116 |
| 41 | Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 832-44 | 10.2 | 340 |
| 40 | Trial Watch: Adoptive cell transfer for anticancer immunotherapy. *OncoImmunology*, **2014**, 3, e28344 | 7.2 | 30 |
| 39 | The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. *Chest*, **2014**, 146, 633-643 | 5.3 | 70 |
| 38 | Trial watch: Immunostimulatory cytokines in cancer therapy. *OncoImmunology*, **2014**, 3, e29030 | 7.2 | 47 |
| 37 | Consensus guidelines for the detection of immunogenic cell death. *OncoImmunology*, **2014**, 3, e955691 | 7.2 | 524 |

| | | | |
|---|---|---|---|
| 36 | Trial Watch: Toll-like receptor agonists in oncological indications. *OncoImmunology*, **2014**, 3, e29179 | 7.2 | 61 |
| 35 | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. *OncoImmunology*, **2014**, 3, e27048 | 7.2 | 64 |
| 34 | Trial Watch: DNA vaccines for cancer therapy. *OncoImmunology*, **2014**, 3, e28185 | 7.2 | 33 |
| 33 | Trial Watch:: Oncolytic viruses for cancer therapy. *OncoImmunology*, **2014**, 3, e28694 | 7.2 | 88 |
| 32 | Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. *Cancer Research*, **2014**, 74, 81-92 | 10.1 | 66 |
| 31 | Trial watch: Dendritic cell-based anticancer therapy. *OncoImmunology*, **2014**, 3, e963424 | 7.2 | 54 |
| 30 | Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. *Cancer Research*, **2014**, 74, 705-15 | 10.1 | 306 |
| 29 | Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. *PLoS ONE*, **2014**, 9, e106914 | 3.7 | 101 |
| 28 | The immune microenvironment of human tumors: general significance and clinical impact. *Cancer Microenvironment*, **2013**, 6, 117-22 | 6.1 | 93 |
| 27 | Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. *Cancer Research*, **2013**, 73, 3499-510 | 10.1 | 215 |
| 26 | Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. *Clinical Cancer Research*, **2013**, 19, 4079-91 | 12.9 | 213 |
| 25 | Trial watch: Dendritic cell-based interventions for cancer therapy. *OncoImmunology*, **2013**, 2, e25771 | 7.2 | 87 |
| 24 | Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. *PLoS ONE*, **2013**, 8, e76928 | 3.7 | 47 |
| 23 | Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. *Frontiers in Immunology*, **2013**, 4, 19 | 8.4 | 48 |
| 22 | Prognostic impact of vitamin B6 metabolism in lung cancer. *Cell Reports*, **2012**, 2, 257-69 | 10.6 | 100 |
| 21 | Tumor microenvironment in NSCLC suppresses NK cells function. *OncoImmunology*, **2012**, 1, 244-246 | 7.2 | 24 |
| 20 | Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. *Nature Medicine*, **2011**, 17, 700-7 | 50.5 | 244 |
| 19 | Tumor microenvironment is multifaceted. *Cancer and Metastasis Reviews*, **2011**, 30, 13-25 | 9.6 | 86 |

| | | | |
|---|---|---|---|
| 18 | Immune infiltration in human cancer: prognostic significance and disease control. *Current Topics in Microbiology and Immunology*, **2011**, 344, 1-24 | 3.3 | 126 |
| 17 | CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 2322-30 | 6.4 | 170 |
| 16 | Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. *Cancer Research*, **2011**, 71, 6391-9 | 10.1 | 196 |
| 15 | Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. *Cancer Research*, **2011**, 71, 5412-22 | 10.1 | 302 |
| 14 | Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. *Journal of Clinical Investigation*, **2010**, 120, 1285-97 | 15.9 | 153 |
| 13 | Characterization of immune functions in TRAF4-deficient mice. *Immunology*, **2008**, 124, 562-74 | 7.8 | 22 |
| 12 | Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. *Genome Biology*, **2008**, 9, R14 | 18.3 | 300 |
| 11 | NKG2C is a major triggering receptor involved in the V[delta]1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. *Aids*, **2008**, 22, 217-26 | 3.5 | 43 |
| 10 | TRAF4 overexpression is a common characteristic of human carcinomas. *Oncogene*, **2007**, 26, 142-7 | 9.2 | 61 |
| 9 | Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. *Blood*, **2002**, 100, 3646-55 | 2.2 | 72 |
| 8 | A non-classical ISRE/ISGF3 pathway mediates induction of RANTES gene transcription by type I IFNs. *FEBS Letters*, **2002**, 511, 41-5 | 3.8 | 22 |
| 7 | Mannose receptor ligand-positive cells express the metalloprotease decysin in the B cell follicle. *Journal of Immunology*, **2001**, 167, 5052-60 | 5.3 | 29 |
| 6 | Retrovirally mediated IFN-beta transduction of macrophages induces resistance to HIV, correlated with up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression. *Journal of Immunology*, **2000**, 164, 1582-7 | 5.3 | 46 |
| 5 | Inhibition of human immunodeficiency virus transmission to CD4+ T cells after gene transfer of constitutively expressed interferon beta to dendritic cells. *Human Gene Therapy*, **2000**, 11, 1695-703 | 4.8 | 3 |
| 4 | Acquired constitutive expression of interferon beta after gene transduction enhances human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity by a RANTES-dependent mechanism. *Human Gene Therapy*, **1999**, 10, 1803-10 | 4.8 | 8 |
| 3 | Interferon-beta-induced human immunodeficiency virus resistance in CD34(+) human hematopoietic progenitor cells: correlation with a down-regulation of CCR-5 expression. *Virology*, **1999**, 253, 241-9 | 3.6 | 13 |
| 2 | Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 11595-600 | 11.5 | 28 |
| 1 | Antiviral activity of autocrine interferon-beta requires the presence of a functional interferon type I receptor. *Journal of Interferon and Cytokine Research*, **1995**, 15, 785-9 | 3.5 | 11 |